67 studies on GHRP-2 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 126 published GHRP-2 COA source records from third-party laboratories, covering 56 publicly attributable vendor identities. Across 113 records with positive numeric purity, the arithmetic mean is 99.31%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 9 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-16. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-19, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $4.75 | $4.00–$5.50 | $0.95 | 2 sources · 2 offers |
| 10 mg | $7.00 | $6.50–$7.50 | $0.70 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-16. Aggregate calculated: 2026-10-19T22:10:48.147811+00:00. Calculation time is not a laboratory observation date.
Within that total, 29 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 9 | 99.18% | 0 of 9 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 7 | 99.44% | 0 of 7 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 4 | 99.51% | 0 of 4 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120831 (99.42%) · #120738 (99.31%) · #116846 (99.43%) · #114777 (99.81%) · #114886 (99.44%) · #112507 (99.13%)
**GHRP-2 may offer a clinically viable, lower-risk alternative to ITT** for diagnosing secondary adrenal insufficiency in patients with hypopituitarism — a group in whom insulin-induced hypoglycemia carries elevated d…
**Peptide secretagogues do not merely turn up GH output — they fundamentally reshape the kinetics of each burst**, a finding with direct implications for dosing strategy. Clinicians and researchers using combined **GH…
**Clinicians and peptide users co-administering testosterone with GHRP-2 should recognize that testosterone itself — not its aromatized or 5alpha-reduced metabolites — is the primary amplifier of GHRP-2-driven pulsati…
**Clinicians managing TBI or SAH survivors should consider routine GH axis screening**, as hypopituitarism and aGHD are far more prevalent in this population than traditionally assumed. The **GHRP-2 test's <9 ng/mL cu…
**Clinicians and biohackers using sermorelin or GHRP-2** should recognize that abdominal fat is the dominant suppressor of combined secretagogue synergy — not simply age or low testosterone. **Reducing AVF before or a…
**The dissociation between GHRP-2's motor-inhibitory and appetite-stimulating effects has direct implications for clinical use.** For practitioners or researchers considering GHRP-2 in protocols targeting appetite or …
**Clinicians and peptide users targeting GH optimization cannot rely on testosterone normalization alone** to restore somatotropic function — AVF and IGF-I levels are independent, dominant modulators. For practitioner…
**GHRP-2's secretagog efficacy is uniquely insensitive to the hormonal and metabolic factors that blunt GHRH-driven GH release**, including visceral adiposity and the IGF-1 / IGFBP axis. For clinicians and researchers…
**Clinicians and researchers testing GH-axis function must control for age, estrogen status, and visceral fat simultaneously** — failing to account for any single factor can produce spurious group differences in secre…
This research highlights a significant potential for GHRP-2 as a therapeutic agent to combat the debilitating muscle wasting associated with severe thermal injuries. By attenuating the expression of key muscle breakdo…
This compelling case report highlights the significant potential of the GHRP-2 test as a highly sensitive and specific diagnostic marker for Cushing's disease, particularly in cases involving ACTH-producing pituitary …
**The antioxidant and anti-inflammatory profile of GHRP-2 does not automatically translate into structural plaque regression** — a critical distinction for anyone considering this peptide as a cardiovascular adjunct. …
**Clinicians and peptide users designing GH-stimulation protocols in women must account for menopausal status and concurrent estrogen exposure, not just dosing of the secretagogue itself.** The finding that GHRP-2 out…
**GHRP-2 cannot substitute for, or add value as, an AVP secretion provocateur**, meaning it should not be used to assess posterior pituitary function in clinical workups for diabetes insipidus or SIADH. Clinicians eva…
**GHRP-2 testing may offer a safer, equally informative alternative to ITT** for evaluating adrenal reserve in patients with hypothalamic or pituitary disease, particularly those for whom insulin-induced hypoglycemia …
**Clinicians and users employing GHRP-2 in hormonal contexts must account for background androgen status**: higher DHT strongly attenuates stimulated cortisol pulsatility, meaning men on 5α-reductase inhibitors (e.g.,…
This research provides compelling evidence that GHRP-2 can directly stimulate ACTH release from the pituitary gland, even when the hypothalamus is impaired. This direct action on the pituitary could make GHRP-2 a valu…
This research highlights the significant potential of GH-Releasing Peptide-2 (GHRP-2) as a safe, rapid, and reliable diagnostic tool for Growth Hormone Deficiency (GHD) in children. Given that the traditional Insulin …
**GHRP-2's protective window — a single subcutaneous dose 30 minutes before injury — highlights a prophylactic or peri-operative protocol angle** relevant to high-risk surgical or septic patients who can be identified…
**Any consumer purchasing this supplement was unknowingly ingesting a WADA-prohibited peptide capable of stimulating the hGH/IGF-1 axis**, with no dosing guidance, safety oversight, or disclosure. For athletes, a posi…
**Finding GHRP-2 in commercially available nutritional supplements** means athletes and consumers may be unknowingly ingesting a non-approved peptide with systemic GH-releasing activity, creating both unintentional do…
**GHRP-2 is an active masking agent for rhGH doping** that can depress a positive isoform test result by more than half — anyone combining GHRP-2 with rhGH for performance enhancement should understand this interactio…
This review solidifies the role of the **GHRP-2 test** as a viable, safe, and convenient diagnostic tool for **adult growth hormone deficiency**, offering an alternative to the more cumbersome insulin tolerance test. …
This study demonstrates a critical nuance in GH secretagogue therapy: simply stimulating a transient pulse of endogenous GH may not be sufficient to drive meaningful clinical outcomes like growth in GHD patients. For …
This research provides a proof-of-concept for creating a longer-lasting version of GHRP-2. For peptide users or clinicians, this could translate to less frequent dosing schedules while maintaining stable levels of gro…
This case study suggests that ghrelin agonists like GHRP-2 may be a valuable therapeutic tool for a specific, challenging subset of anorexia nervosa patients: those who have overcome the psychological fear of food but…
The study demonstrates two distinct and effective pharmacological pathways to combat growth retardation caused by somatotropic axis deficiency. For users of growth hormone secretagogues, this provides evidence that **…
The GHRP-2 test emerges as a viable diagnostic tool for secondary adrenal failure, offering diagnostic power comparable to the established CRH stimulation test. For clinicians, this provides another option for assessi…
For athletes and regulatory bodies, this research provides a pathway to more effective and reliable anti-doping controls for hGH. The identification of `RAB31` and `FN1` as robust biomarkers could lead to new testing …
This research provides a cellular mechanism for ghrelin analogs like GHRP-2 exerting anti-inflammatory effects within the ovary. For biohackers or clinicians interested in female reproductive health, this suggests a p…
This research suggests that the GHRP-2 stimulation test could be a valuable addition to the diagnostic toolkit for TSH-producing pituitary adenomas, especially when traditional tests like the TRH test are inconclusive…
The identification of this novel GHRP-2 analogue highlights a concerning trend in illicit drug manufacturing: the deliberate modification of known prohibited substances to create 'designer' peptides that can evade det…
The findings suggest that the GHRP-2 test can replace the riskier insulin tolerance test for HPA axis assessment, but its application is highly specific. **Clinicians can consider using the GHRP2T in male patients wit…
This case highlights that serious endocrine disorders like **isolated ACTH deficiency** can manifest with vague, non-classical symptoms such as stomach discomfort, which are commonly attributed to more benign conditio…
This research provides a crucial tool for anti-doping agencies to identify the use of black market follistatin. The discovery that all tested genuine products contain His-tags is a game-changer for testing, as it prov…
The findings suggest that the `GHRP-2 test` is more than just a binary diagnostic tool for severe **AGHD**; it's a quantitative prognostic marker. For clinicians managing patients with **NFPA**, a very low peak GH res…
This automated system significantly enhances the capabilities of anti-doping programs. By enabling reliable, quantitative analysis from Dried Blood Spot samples, it makes collection less invasive and sample handling m…
Free, no account — handy when you're working with GHRP-2.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account